Newsroom

⁹⁹ᵐTc-Maraciclatide Demonstrates Potential to Differentiate Inflammation from Fibrosis in Interstitial Lung Disease

Phase 2 ^99mTc-maraciclatide data presented at SNMMI 2026 Annual Meeting show distinct αvβ3 integrin uptake in patients with ILD

Serac Healthcare Limited has presented Phase 2 data showing that SPECT-CT imaging with ^99mTc-maraciclatide has the potential to identify and differentiate active inflammation from fibrosis in patients with interstitial lung disease (ILD). The findings were presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Los Angeles, USA, taking place from 30 May to 2 June and have been highlighted in an SNMMI press release: “New SPECT Imaging Approach Distinguishes Inflammation from Fibrosis to Optimize Treatment for Lung Disease.”

 First US Presentation of DETECT Data Demonstrates Semi-Quantitative Assessment of Endometriosis Lesions Using ⁹⁹ᵐTc-Maraciclatide

Poster presented at SNMMI 2026 shows standardised uptake metrics align with lesion type and expected levels of angiogenesis, including for superficial peritoneal disease.

Serac Healthcare Limited announces the presentation of a poster at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting reporting semi-quantitative imaging data from the DETECT Phase 2 study of ^99mTc-maraciclatide in endometriosis.

⁹⁹ᵐTc-maraciclatide Abstracts To be Presented at SNMMI 2026

Serac Healthcare Limited announces that two abstracts on ^99mTc-maraciclatide will be presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting taking place from 30 May to 2 June in Los Angeles, USA.

Endometriosis Imaging Study Published in The Lancet Obstetrics, Gynaecology & Women’s Health Highlights ⁹⁹ᵐTc-maraciclatide as a Promising Diagnostic and Monitoring Tool

Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, ^99mTc-maraciclatide, and the Nuffield Department of Women’s & Reproductive Health at the University of Oxford announce the journal publication of Phase 2 data from the “Detecting Endometriosis expressed inTegrins using teChneTium-99m” (DETECT) imaging study. The paper, published open access online in The Lancet Obstetrics, Gynaecology & Women’s Health, highlights that ^99mTc-maraciclatide has potential as...

Endometriosis Imaging with ⁹⁹ᵐTc-maraciclatide Presented at European Endometriosis Congress 2026

Serac Healthcare Limited announces that two oral presentations on the “Detecting Endometriosis expressed inTegrins using teChneTium-99m” imaging (DETECT) study, have been presented at the 8^th European Endometriosis Congress which took place from 23^rd to 25^th April in Bologna, Italy.

DETECT Abstracts Selected for Oral Presentation at European Endometriosis Congress 2026

Serac Healthcare Limited announces that two abstracts on the “Detecting Endometriosis expressed inTegrins using teChneTium-99m” imaging (DETECT) study, have been selected for oral presentation in the “Best Submitted Abstracts” sessions at the 8^th European Endometriosis Congress taking place from 23^rd to 25^th April in Bologna, Italy.